The cost utility of autologous chondrocytes implantation using ChondroCelect® in symptomatic knee cartilage lesions in Belgium

PharmacoEconomics

Volumn 28, Issue 12, 2010, Pages 1129-1146

  Gerlier, Laetitia ^a   Lamotte, Mark ^a   Wille, Micheline ^b   Kreuz, Peter C ^c   Vanlauwe, Johan ^d   Dubois, Dominique ^e   Meurgey, Franois M ^f  

^a IQVIA   (United States)

^b TiGenix   (Belgium)

^c University Medical Center Rostock   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Patient Value Solutions ^*  (Belgium)

^f Oukelos SPRL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; AUTOLOGOUS CHONDROCYTE IMPLANTATION; BELGIUM; CELL THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; ECONOMIC EVALUATION; GRAFT FAILURE; HEALTH CARE; HEMARTHROSIS; HEMATOMA; HOSPITAL COST; HUMAN; HYALINE CARTILAGE; INTERVENTION STUDY; KNEE CARTILAGE LESION; KNEE FRACTURE; KNEE INJURY; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE PROSTHESIS; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MICROFRACTURE; OUTCOME ASSESSMENT; PHYSIOTHERAPY; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; REOPERATION; SCORING SYSTEM; SENSITIVITY ANALYSIS; SHORT FORM 36; SURGICAL TECHNIQUE; SYMPTOM; TISSUE ADHESION; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ARTHROPLASTY, REPLACEMENT, KNEE; BELGIUM; CARTILAGE, ARTICULAR; CHONDROCYTES; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; KNEE INJURIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 78649286687     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584920-000000000-00000     Document Type: Article

References (70)

1. Hjelle K, Solheim E, Strand T, et al. Articular cartilage defects in 1000 knee arthroscopies. Arthroscopy 2002 Sep; 18(7):730-4
2. Widuchowski W, Widuchowski J, Trzaska T. Articular cartilage defects: study of 25 124 knee arthroscopies. Knee 2007 Jun; 14(3):177-82
3. Widuchowski W, Lukasik P, Kwiatkowski G, et al. Isolated full thickness chondral injuries: prevalance and outcome of treatment. A retrospective study of 5233 knee arthroscopies. Acta Chir Orthop Traumatol Cech 2008 Oct; 75(5):382-6
4. Arøen A, Løken S, Heir S, et al. Articular cartilage lesions in 993 consecutive knee arthroscopies. Am J Sports Med 2004 Jan-Feb; 32(1):211-5
5. Curl WW, Krome J, Gordon S, et al. Cartilage injuries: a review of 31 516 knee arthroscopies. Arthroscopy 1997;13:456-60
6. Disler DG, McCauley TR, Kelman CG, et al. Fat-suppressed three-dimensional spoiled gradient-echo MR imaging of hyaline cartilage defects in the knee: comparison with standard MR imaging and arthroscopy. AJR Am J Roentgenol 1996;167(1):127-32
7. Shelbourne KD, Jari S, Gray T. Outcome of untreated traumatic articular cartilage defects of the knee: a natural history study. J Bone Joint Surg Am 2003;85-A Suppl. 2:8-16
8. Buckwalter JA, Lane NE. Athletics and osteoarthritis. Am J Sports Med 1997;25:873-81
9. Gelber AC, Hochberg MC, Mead LA, et al. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med 2000;133:321-8
10. Vanlauwe J, Almqvist F, Bellemans J, et al. Repair of symptomatic cartilage lesions of the knee: the place of autologous chondrocyte implantation. Acta Orthop Belg 2007 Apr; 73(2):145-58
11. Steadman JR, Rodkey WG, Rodrigo JJ. Microfracture: surgical technique and rehabilitation to treat chondral defects. Clin Orthop 2001;391 S: S362-9
12. Hangody L, Fules P. Autologous osteochondral mosaicplasty for the treatment of full-thickness defects of weight-bearing joints: ten years of experimental and clinical experience. J Bone Joint Surg Am 2003;85-A Suppl. 2:25-32
13. Clar C, Cummins E, McIntyre L, et al. Clinical and costeffectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation. Health Technol Assess 2005 Dec; 9(47): iii-iiv, ix-x, 1-82
14. Williams 3rd RJ, Harnly HW. Microfracture: indications, technique, and results. Instr Course Lect 2007;56:419-28
15. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994 Oct. 6; 331(14):889-95
16. Jones DG, Peterson L. Autologous chondrocyte implantation. J Bone Joint Surg Am 2006;88(11):2501-20
17. Knutsen G, Drogset JO, Engebretsen L, et al. A randomized trial comparing autologous chondrocyte implantation with microfracture: findings at five years. J Bone Joint Surg Am 2007 Oct; 89(10):2105-12
18. Saris D, Vanlauwe J, Victor J, et al. Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. Am J Sports Med 2008;36:235-46
19. Basad E, Stürz H, Steinmeyer J. Die behandlung chondraler defekte mit MACI oder microfracture-erste Ergebnisse einer vergleichenden klinischen Studie. Orthopädische Praxis 2004;40:6-10
20. Horas U, Pelinkovic D, Herr G, et al. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint: a prospective, comparative trial. J Bone Joint Surg Am 2003;85:185-92
21. Bentley G, Biant LC, Carrington RW, et al. A prospective, randomized comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. J Bone Joint Surg Br 2003;85(2):223-30
22. Peterson L, Minas T, Brittberg M, et al. Two-to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 2000;374:212-34
23. Minas T. Chondrocyte implantation in the repair of chondral lesions of the knee: economics and quality of life. Am J Orthop 1998;27:379-44
24. Vavken P, Gruber M, Dorotka R. Tissue engineering in orthopaedic surgery: clinical effectiveness and cost effectiveness of autologous chondrocyte transplantation [in German]. Z Orthop Unfall 2008 Jan-Feb; 146(1):26-30
25. Cleemput I, Van Wilder P, Vrijens F, et al. Recommandations pour les évaluations pharmacoéconomiques en Belgique. Health technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE), 2008. KCE reports 78B
26. Saris DB, Vanlauwe J, Victor J, et al., TIG/ACT/01/2000&EXT Study Group. Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared to microfracture. Am J Sports Med 2009 Nov; 37 Suppl. 1:10S-19S
27. Messner K, Maletius W. The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes. Acta Orthop Scand 1996 Apr; 67(2):165-8
28. Prakash D, Learmonth D. Natural progression of osteochondral defect in the femoral condyle. Knee 2002 Feb; 9(1):7-10
29. Fu FH, Zurakowski D, Browne JE, et al. Autologous chondrocyte implantation versus debridement for treatment of full-thickness chondral defects of the knee: an observational cohort study with 3-year follow-up. Am J Sports Med 2005 Nov; 33(11):1658-66
30. Dozin B, Malpeli M, Cancedda R, et al. Comparative evaluation of autologous chondrocyte implantation and mosaicplasty: a multicentered randomized clinical trial. Clin J Sport Med 2005 Jul; 15(4):220-6
31. US Department of Health and Human Services. National Institute of Health. NIH Consensus Development Program. NIH Consensus Development Conference on Total Knee Replacement [online]. Available from URL:http://consensus.nih.gov/ 2003/2003TotalKneeReplacement117html.htm [Accessed 2010 Jul. 23]
32. Mahomed NN, Barrett J, Katz JN, et al. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am 2005 Jun; 87(6):1222-8
33. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 2003 Nov. 3; 1:64
34. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS): validation and comparison to the WOMAC in total knee replacement. Health Qual Life Outcomes 2003 May 25; 1:17
35. Brun P, Dickinson SC, Zavan B, et al. Characteristics of repair tissue in second-look and third-look biopsies from patients treated with engineered cartilage: relationship to symptomatology and time after implantation. Arthritis Res Ther 2008;10(6):R132
36. Fritz J, Janssen P, Gaissmaier C, et al. Articular cartilage defects in the knee: basics, therapies and results. Injury 2008 Apr; 39 Suppl. 1: S50-7
37. Steadman JR, Briggs KK, Rodrigo JJ, et al. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy 2003;19:477-84
38. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 Mar; 21(2):271-92
39. Analytical Methods Committee (AMC). Fitting a linear functional relationship to data with error on both variables [technical brief no. 10]. London: Royal Society of Chemistry, 2002
40. Ruchlin HS, Insinga RP. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 2008;26(11):925-35
41. Brazier JE, Harper R, Munro J, et al. Generic and conditionspecific outcome measures for people with osteoarthritis of the knee. Rheumatology 1999 Sep; 38(9):870-7
42. ® [abstract no. A553]. Value Health 2008 Nov; 11(6):A553
43. Bennett KJ, Torrance GW, Moran L-A, et al. Health state utilities in knee replacement surgery: the development and evaluation of McKnee. J Rheumatol 1997;24:1796-805
44. Donell ST, Neyret P, Dejour H, et al. The effect of age on the quality of life after knee replacement. Knee 1998;5(2):125-8
45. Drewett RF, Minns RJ, Sibly TF. Measuring outcome of total knee replacement using quality of life indices. Ann R Coll Surg Engl 1992 Jul; 74(4):286-90
46. Lavernia CJ, Guzman JF, Gachupin-Garcia A. Cost effectiveness and quality of life in knee arthroplasty. Clin Orthop Relat Res 1997;345:134-9
47. Räsänen P, Paavolainen P, Sintonen H, et al. Effectiveness of hip or knee replacement surgery in terms of qualityadjusted life years and costs. Acta Orthop 2007;78(1):108-15
48. Belgian public health insurance (INAMI/RIZIV) [online]. Available from URL:http://www.inami.fgov. be/fr/search.asp [Accessed 2010 Sep. 20]
49. Financiele feedback per pathologie. All patient-related diagnosis-related group (APR-DRG) [online]. Available from URL:https://tct.fgov. be/etct/anonymous?lang=nl [Accessed 2010 Sep. 20]
50. Haddo O, Mahroof S, Higgs D, et al. The use of chondrogide membrane in autologous chondrocyte implantation. Knee 2004;11:51-5
51. Data on file, IMS Health Consulting, 2008 Jul
52. Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000 Dec; 39 Suppl. 2:51-6
53. Leardini G, Salaffi F, Caporali R, et al., Italian Group for Study of the Costs of Arthritis. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol 2004 Nov-Dec; 22(6):699-706
54. Núñez M, Núñez E, Segur JM, et al. Health-related quality of life and costs in patients with osteoarthritis on waiting list for total knee replacement. Osteoarthritis Cartilage 2007 Mar; 15(3):258-65
55. Rabenda V, Manette C, Lemmens R, et al. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 2006 Jun; 33(6):1152-8
56. SooHoo NF, Lieberman JR, Ko CY, et al. Factors predicting complication rates following total knee replacement. J Bone Joint Surg Am 2006 Mar; 88(3):480-5
57. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Country-specific pharmacoeconomic guidelines, country selection [online]. Available from URL:http://www.ispor.org/PEguidelines/COUNTRYSPECIFIC. asp [Accessed 2010 Sep. 20]
58. Gross domestic product (GDP) at market prices, year 2008. Data extracted from the Eurostat website, on 2009 Oct. 23 [online]. Available from URL:http://epp. eurostat.ec.europa.eu/portal/page/portal/national-accounts/data/ database [Accessed 2010 Sep. 20]
59. Jakobsen RB, Engebretsen L, Slauterbeck JR. An analysis of the quality of cartilage repair studies. J Bone Joint Surg Am 2005;87:2232-9
60. Peterson L, Brittberg M, Kiviranta I, et al. Autologous chondrocyte transplantation: biomechanics and long-term durability. Am J Sports Med 2002;30:2-12
61. Cleemput I, Neyt M, Thiry N, et al. Threshold values for cost-effectiveness in health care. Brussels: Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2008. KCE reports 100A (D/2008/10.273/94)
62. WHO. Making choices in health: WHO guide to costeffectiveness analysis. Geneva: WHO, 2003
63. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26(9):733-44
64. Williams A. What could be nicer than NICE? London: Office of Health Economics, 2004
65. Duffy GP, Trousdale RT, Stuart MJ. Total knee arthroplasty in patients 55 years old or younger: 10-to 17-year results. Clin Orthop 1998;356:22-7
66. Ranawat CS, Flynn WF, Saddler S, et al. Long-term results of the total condylar knee arthroplasty. Clin Orthop 1993;268:94-102
67. Stern SH, Bowen MK, Insall JN, et al. Cemented total knee arthroplasty for gonarthrosis in patients aged 55. Clin Orthop 1990;260:124-9
68. Vavken P, Dorotka R, Grüber M. Economic modeling and decision making in the development and clinical application of tissue engineering. In: Meyer U, Handschel J, Meyer T, et al., editors. Fundamentals of tissue engineering and regenerative medicine. New York: Springer, 2009:13-21
69. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010;28(2):113-42
70. Committee for Advanced Therapies (CAT), CAT Scientific Secretariat, Schneider CK, et al. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 2010 Mar; 9(3):195-201